In the last three months, Ginkgo Bioworks' (NYSE: DNA) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and ...

The company's cell engineering platform combines robotics and artificial intelligence (AI) to produce new cell lines for its clients. This is important because many top-selling drugs are manufactured ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It has been difficult to be a shareholder of Ginkgo Bioworks (NYSE: DNA) over the past year. The stock has collapsed about 72% from its peak last summer. The company's cell engineering foundry is an ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ginkgo Bioworks is still struggling with operating efficiency. Management is signaling that its processes may be streamlined. This isn't the right dip-buying opportunity for everyone. Is that the case ...